Healthcare products major Novartis International AG, (NVS), said that its pivotal late-stage trial, BOLERO-3 (Breast cancer trials of OraLEveROlimus-3) met the primary endpoint.
The findings from the study showed that adding everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine significantly extended progression-free survival or PFS when compared to treatment with placebo plus trastuzumab and vinorelbine. The treatment regimen included Afinitor (everolimus) tablets in women with receptor-2 positive (HER2 positive) advanced breast cancer who received prior taxane therapy and whose disease is resistant to prior trastuzumab (Herceptin treatment).
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.